Financial
FY2025 revenue $20.62bn (+4.8%); operating margin 13.4%; net income $2.08bn.
Cash $4.51bn; debt $10.00bn.
GE HealthCare
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Strong
Customer rating
No reviews yet
Financial health
Band: StrongListed: GEHC
FY2025 revenue $20.62bn (+4.8%); operating margin 13.4%; net income $2.08bn.
Cash $4.51bn; debt $10.00bn.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$20.6bn | +4.8% | US$2.8bn | US$2.1bn | GE HealthCare Technologies |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
No adverse media involving GE HealthCare found in HSH's search of the last 24 months.
Cyber & information governance
Mar 2026: GE HealthCare began a US recall of certain Revolution CT systems over a potential security vulnerability in AW Server deployed via its Edison Health Link CT subscription. NHS DSPT status not yet checked.
Regulatory & clinical safety
Aug 2026: GE HealthCare began a US Class 2 recall of some Senographe Pristina mammography systems, as a configuration issue could cause image artefacts or a minor extra x-ray dose.
Contract performance
No notable contract disputes, terminations or troubled implementations involving GE HealthCare found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.